$RVMD
Revolution Medicines Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021026054 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $10.13M $11.55M
YoY Change -12.26% -12.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.670M $5.170M
YoY Change 29.01% 113.64%
% of Gross Profit
Research & Development $40.86M $27.46M
YoY Change 48.81% 29.6%
% of Gross Profit
Depreciation & Amortization $671.0K $632.0K
YoY Change 6.17% 20.15%
% of Gross Profit
Operating Expenses $47.53M $32.63M
YoY Change 45.67% 38.24%
Operating Profit -$37.40M -$21.08M
YoY Change 77.39% 102.01%
Interest Expense $12.00K $21.00K
YoY Change -42.86% -93.23%
% of Operating Profit
Other Income/Expense, Net $221.0K $888.0K
YoY Change -75.11% 191.15%
Pretax Income -$37.18M -$20.19M
YoY Change 84.09% 99.33%
Income Tax $0.00 -$675.0K
% Of Pretax Income
Net Earnings -$37.18M -$19.52M
YoY Change 90.46% 92.67%
Net Earnings / Revenue -366.95% -169.05%
Basic Earnings Per Share
Diluted Earnings Per Share -$528.0K -$330.8K
COMMON SHARES
Basic Shares Outstanding 73.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $681.6M $347.9M
YoY Change 95.92%
Cash & Equivalents $351.6M $182.7M
Short-Term Investments $330.0M $165.3M
Other Short-Term Assets $8.200M $5.700M
YoY Change 43.86%
Inventory
Prepaid Expenses
Receivables $7.600M
Other Receivables $0.00
Total Short-Term Assets $697.4M $362.1M
YoY Change 92.6%
LONG-TERM ASSETS
Property, Plant & Equipment $37.60M $15.20M
YoY Change 147.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $700.0K
YoY Change 100.0%
Total Long-Term Assets $114.3M $92.20M
YoY Change 23.97%
TOTAL ASSETS
Total Short-Term Assets $697.4M $362.1M
Total Long-Term Assets $114.3M $92.20M
Total Assets $811.7M $454.3M
YoY Change 78.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.700M $7.900M
YoY Change 22.78%
Accrued Expenses $24.00M $16.40M
YoY Change 46.34%
Deferred Revenue $9.964M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K
YoY Change
Total Short-Term Liabilities $43.76M $41.50M
YoY Change 5.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.439M $20.40M
YoY Change -92.95%
Total Long-Term Liabilities $1.439M $20.40M
YoY Change -92.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.76M $41.50M
Total Long-Term Liabilities $1.439M $20.40M
Total Liabilities $89.07M $69.00M
YoY Change 29.09%
SHAREHOLDERS EQUITY
Retained Earnings -$302.7M
YoY Change
Common Stock $1.025B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $722.6M $385.3M
YoY Change
Total Liabilities & Shareholders Equity $811.7M $454.3M
YoY Change 78.66%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$37.18M -$19.52M
YoY Change 90.46% 92.67%
Depreciation, Depletion And Amortization $671.0K $632.0K
YoY Change 6.17% 20.15%
Cash From Operating Activities -$37.25M -$28.02M
YoY Change 32.94% 122.28%
INVESTING ACTIVITIES
Capital Expenditures $3.579M $603.0K
YoY Change 493.53% 76.83%
Acquisitions
YoY Change
Other Investing Activities $5.890M -$59.11M
YoY Change -109.96% -1069.02%
Cash From Investing Activities $2.309M -$59.72M
YoY Change -103.87% -1136.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $281.7M $253.7M
YoY Change 11.03% 1812164.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 282.3M 253.7M
YoY Change 11.24% 1812357.14%
NET CHANGE
Cash From Operating Activities -37.25M -28.02M
Cash From Investing Activities 2.309M -59.72M
Cash From Financing Activities 282.3M 253.7M
Net Change In Cash 247.3M 166.0M
YoY Change 48.98% -2530.6%
FREE CASH FLOW
Cash From Operating Activities -$37.25M -$28.02M
Capital Expenditures $3.579M $603.0K
Free Cash Flow -$40.83M -$28.62M
YoY Change 42.64% 121.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18784000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28294000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28992000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1439000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
632000
CY2020Q4 us-gaap Liabilities
Liabilities
92725000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10131000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11546000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40858000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27457000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6670000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27435000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8481000
CY2021Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7564000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60945000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
305000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47176000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1084000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3672000
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6393000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3700000
CY2020Q4 us-gaap Goodwill
Goodwill
14608000
CY2020Q4 us-gaap Assets
Assets
567401000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12609000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9964000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12111000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43759000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8135000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7444000
CY2021Q1 us-gaap Liabilities
Liabilities
89071000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
116000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302721000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1025230000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
740098000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
722580000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
63000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265545000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
474676000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811651000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
567401000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73435109
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66599748
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73435109
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66599748
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5171000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
47528000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
32628000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37397000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21082000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
233000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
909000
CY2021Q1 us-gaap Interest Expense
InterestExpense
12000
CY2020Q1 us-gaap Interest Expense
InterestExpense
21000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
221000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
888000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37176000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20194000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-675000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37176000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19519000
CY2020Q1 rvmd Redeemable Convertible Preferred Stock Dividends Undeclared And Cumulative
RedeemableConvertiblePreferredStockDividendsUndeclaredAndCumulative
2219000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37176000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21738000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70420076
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29297698
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37229000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19557000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
555000
CY2021Q1 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
46000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3387000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-152574000
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
305109000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020Q1 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
47000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1567000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
385316000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-37176000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-19519000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
267000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
267000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3387000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1567000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
671000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
632000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-534000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
105000
CY2021Q1 rvmd Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
740000
CY2020Q1 rvmd Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
645000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1171000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-287000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1257000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3202000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2131000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3084000
CY2021Q1 rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
46000
CY2020Q1 rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
47000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
882000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
37000
CY2021Q1 rvmd Unpaid Offering Costs
UnpaidOfferingCosts
564000
CY2020Q1 rvmd Unpaid Offering Costs
UnpaidOfferingCosts
1417000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1200000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-963000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2493000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3033000
CY2020Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
716000
CY2021Q1 rvmd Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-670000
CY2020Q1 rvmd Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-775000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
853000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37246000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28018000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
114038000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
100038000
CY2021Q1 rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
119926000
CY2020Q1 rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
40925000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3579000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
603000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2309000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59716000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
281709000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
253717000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
555000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
27000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282264000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
253744000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
247327000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
166010000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105352000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16873000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
352679000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
182669000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1084000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
214000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
352679000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
182883000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16972000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8740000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8070000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3237000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7736000
CY2021Q1 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15915000
CY2020Q4 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
10459000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#8217;s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#8217;s condensed consolidated financial statements as of and for the three months ended March 31, 2021. Actual results could materially differ from the Company&#8217;s estimates, and there may be changes to the estimates in future periods<font style="font-style:italic;">.</font> </p>
CY2021Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent accounting pronouncements not yet adopted</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,<font style="font-style:italic;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </font>(ASU 2016-13),&#160;which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No.&#160;2018-19, <font style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses</font> (ASU 2018-19) which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05,<font style="font-style:italic;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Targeted Transition Relief </font>(ASU 2019-05). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. ASU 2016-13 is applicable to the Company for the fiscal year beginning after December&#160;15, 2021. Early adoption is permitted.&#160;The Company is currently evaluating the impact the adoption of these ASUs will have on its consolidated financial statements and related disclosures. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU&#160;No.&#160;2018-15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other-Internal-Use Software (Subtopic&#160;350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software.&#160;This ASU is effective for the Company for the fiscal year beginning after December&#160;15, 2020, and interim periods within fiscal years beginning after December&#160;31, 2021. The Company is currently evaluating the impact of this ASU on the Company&#8217;s consolidated financial statements. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued ASU 2020-08, <font style="font-style:italic;">Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs</font> (ASU 2020-08). This ASU clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company is currently evaluating the impact of ASU 2020-08 on the Company&#8217;s consolidated financial statements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, FASB issued ASU 2020-10, <font style="font-style:italic;">Codification Improvements </font>(ASU 2020-10). This update contains amendments that improve the consistency of the Codification by including all disclosure guidance in the appropriate Disclosure Section (Section 50). Many of the amendments arose because the Board provided an option to give certain information either on the face of the financial statements or in the notes to financial statements and that option only was included in the Other Presentation Matters Section (Section 45) of the Codification. The option to disclose information in the notes to financial statements should have been codified in the Disclosure Section as well as the Other Presentation Matters Section (or other Section of the Codification in which the option to disclose in the notes to financial statements appears). The amendments in this Update do not change GAAP and, therefore, are not expected to result in a significant change in practice. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early adoption is permitted. Adoption shall be applied retrospectively. The Company is currently evaluating the impacts of the provisions of ASU 2020-10 on its consolidated financial statements and related disclosures.</p>
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2055
CY2020Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-4.8661
CY2021Q1 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2020Q4 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
682198000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
91000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
682261000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
441963000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
131000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
442079000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19619000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1189000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
492000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
104000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
97000
CY2021Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2602000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4878000
CY2021Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P4Y7M6D
CY2021Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
801000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1069000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1069000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1069000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
870000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2335000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5145000
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P4Y9M18D
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2021Q1 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
0
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
31994000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32664000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
19000
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
rvmd:AccruedResearchAndDevelopmentExpenseCurrent
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
19000
CY2021Q1 rvmd Lease Liabilities
LeaseLiabilities
31994000
CY2020Q4 rvmd Lease Liabilities
LeaseLiabilities
32683000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
800000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
600000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
400000
CY2021Q1 rvmd Tenant Improvement Allowance Credits
TenantImprovementAllowanceCredits
100000
CY2020Q1 rvmd Tenant Improvement Allowance Credits
TenantImprovementAllowanceCredits
100000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3454000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5144000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4173000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4215000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4363000
CY2021Q1 rvmd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
24213000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
45562000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12264000
CY2021Q1 rvmd Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
1304000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote
CY2021Q1 rvmd Number Of Voting Rights Per Common Share
NumberOfVotingRightsPerCommonShare
1
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14338545
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10511256
CY2021Q1 rvmd Shares Of Common Stock Subject To Repurchase
SharesOfCommonStockSubjectToRepurchase
95936
CY2020Q4 rvmd Shares Of Common Stock Subject To Repurchase
SharesOfCommonStockSubjectToRepurchase
130793
CY2021Q1 rvmd Exercise Price Of Early Exercised Shares Of Common Stock
ExercisePriceOfEarlyExercisedSharesOfCommonStock
200000
CY2020Q4 rvmd Exercise Price Of Early Exercised Shares Of Common Stock
ExercisePriceOfEarlyExercisedSharesOfCommonStock
200000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
46300000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3387000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1567000
CY2021Q1 rvmd Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
70534554
CY2020Q1 rvmd Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
29616684
CY2021Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
114478
CY2020Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
318986
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6434432
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5860704

Files In Submission

Name View Source Status
0001564590-21-026054-index-headers.html Edgar Link pending
0001564590-21-026054-index.html Edgar Link pending
0001564590-21-026054.txt Edgar Link pending
0001564590-21-026054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvmd-10q_20210331.htm Edgar Link pending
rvmd-20210331.xml Edgar Link completed
rvmd-20210331.xsd Edgar Link pending
rvmd-20210331_cal.xml Edgar Link unprocessable
rvmd-20210331_def.xml Edgar Link unprocessable
rvmd-20210331_lab.xml Edgar Link unprocessable
rvmd-20210331_pre.xml Edgar Link unprocessable
rvmd-ex311_7.htm Edgar Link pending
rvmd-ex312_9.htm Edgar Link pending
rvmd-ex321_8.htm Edgar Link pending
rvmd-ex322_6.htm Edgar Link pending
Show.js Edgar Link pending